2.35 USD
↗ 0.08 (3.52%)AT CLOSE (03:59 PM EDT)
Larimar Therapeutics, Inc. Common Stock
LRMRNASDAQ • USD
2.35
↗ 0.00 (0.00%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
2.35
↗ 0.00 (0.00%)
Market: CLOSED
LRMR is currently priced at $2.35. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, LRMR appears attractively valued relative to sector peers across key multiples.
Technical & fundamental data as of Oct 23, 2026.
Open?$2.27
High?$2.37
Low?$2.22
Prev. Close?$2.27
Volume?1.1M
Avg. Volume?1.6M
VWAP?$2.30
Rel. Volume?0.70x
Bid / Ask
Bid?$2.28 × 200
Ask?$2.38 × 300
Spread?$0.10
Midpoint?$2.33
Valuation & Ratios
Market Cap?244.1M
Shares Out?103.9M
Float?61.7M
Float %?59.4%
P/E Ratio?N/A
P/B Ratio?1.92
EPS?-$1.66
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Employees
71
Market Cap
235.8M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2020-05-29
Address
THREE BALA PLAZA EAST. SUITE 506
BALA CYNWYD, PA 19004
Phone: 844-511-9056
BALA CYNWYD, PA 19004
Phone: 844-511-9056
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?20
Piotroski F-Score?0/9Weak
Altman Z-Score?-3.13Distress
Confidence?54%Low
Short InterestSqueeze Risk
Short % of Float?24.92%Squeeze Risk
Short Interest?15.4M
Days to Cover?8.7
Free Float61.7M
Avg Daily Volume1.8M
Settlement Date2026-09-30
Financial Health
Current Ratio?4.70Strong
Quick Ratio?4.70Strong
Cash Ratio?2.71Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.92CHEAP▾
Peers100
S&P76
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-0.9CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-135.5%WEAK▾
S&P3
ROA?-104.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-156077000
Enterprise Value?$151.4M
Fundamentals ratios updated end of day